Evidence map›Paper›PMID 38638138›Full record

ArticleFrontiers in endocrinology2024

Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication.

Alisher Ikramov, Shakhnoza Mukhtarova, Raisa Trigulova, Dilnoza Alimova, Saodat Abdullaeva

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alisher IkramovDepartment of Mathematics, New Uzbekistan University, Tashkent, Uzbekistan.
Shakhnoza MukhtarovaLaboratory of Cardiodiabetes, Republican Specialized Scientific and Practical Medical Center for Cardiology, Tashkent, Uzbekistan.
Raisa TrigulovaLaboratory of Cardiodiabetes, Republican Specialized Scientific and Practical Medical Center for Cardiology, Tashkent, Uzbekistan.
Dilnoza AlimovaLaboratory of Cardiodiabetes, Republican Specialized Scientific and Practical Medical Center for Cardiology, Tashkent, Uzbekistan.
Saodat AbdullaevaLaboratory of Cardiodiabetes, Republican Specialized Scientific and Practical Medical Center for Cardiology, Tashkent, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood glycosylated hemoglobin level can be affected by various factors in patients with type 2 diabetes and cardiovascular diseases. Frequent measurements are expensive, and a suitable estimation method could improve treatment outcomes. Patients and methods: 93 patients were recruited in this research. We analyzed a number of parameters such as age, glucose level, blood pressure, Body Mass Index, cholesterol level, echocardiography et al. Patients were prescribed metformin. One group (n=60) additionally was taking sitagliptin. We applied eight machine learning methods (k nearest neighbors, Random Forest, Support Vector Machine, Extra Trees, XGBoost, Linear Regression including Lasso, and ElasticNet) to predict exact values of glycosylated hemoglobin in two years. Results: We applied a feature selection approach using step-by-step removal of them, Linear Regression on remaining features, and Pearson's correlation coefficient on the validation set. As a result, we got four different subsets for each group. We compared all eight Machine Learning methods using different hyperparameters on validation sets and chose the best models. We tested the best models on the external testing set and got R Conclusion: The resulting algorithms could be used to assist clinical decision-making on prescribing anti-diabetic medications in pursuit of achieving glycemic control.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2MetforminGlycated HemoglobinHumansSitagliptin PhosphateGlycated HemoglobinMetforminSitagliptin Phosphatediabetes mellitusglycosylated hemoglobinmetforminrandom forestsitagliptin

Identifiers

PMID38638138
PMCPMC11024317

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.